Joseph Todisco's Insider Trades & SAST Disclosures
Joseph Todisco's most recent trade in CorMedix Inc was a trade of 59,170 Common Stock done at an average price of $3.4 . Disclosure was reported to the exchange on April 1, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Joseph Todisco.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| CorMedix Inc | Joseph Todisco | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.38 per share. | 01 Apr 2025 | 59,170 | 530,721 (2%) | 0% | 3.4 | 199,995 | Common Stock |
| CorMedix Inc | Joseph Todisco | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2025 | 59,170 | 440,830 | - | - | Stock Option (Right to Buy Common Stock) | |
| CorMedix Inc | Joseph Todisco | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jan 2025 | 187,500 | 495,528 (1%) | 0% | 0 | Common Stock | |
| CorMedix Inc | Joseph Todisco | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.17 per share. | 17 Jan 2025 | 23,977 | 471,551 (1%) | 0% | 12.2 | 291,800 | Common Stock |
| CorMedix Inc | Joseph Todisco | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.19 per share. | 10 Jan 2025 | 17,829 | 308,028 (1%) | 0% | 11.2 | 199,507 | Common Stock |
| CorMedix Inc | Joseph Todisco | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.17 per share. | 10 May 2024 | 26,982 | 325,857 (1%) | 0% | 5.2 | 139,497 | Common Stock |
| CorMedix Inc | Joseph Todisco | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 3.74 per share. | 13 Mar 2024 | 13,561 | 352,839 (1%) | 0% | 3.7 | 50,718 | Common Stock |
| CorMedix Inc | Todisco Joseph | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2024 | 266,667 | 266,667 | - | - | Stock Option (Right to Buy Common Stock) | |
| CorMedix Inc | Todisco Joseph | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2024 | 133,333 | 353,059 (1%) | 0% | 0 | Common Stock | |
| CorMedix Inc | Joseph Todisco | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.47 per share. | 12 Jan 2024 | 13,781 | 339,278 (1%) | 0% | 3.5 | 47,820 | Common Stock |
| CorMedix Inc | Joseph Todisco | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 4.58 per share. | 17 May 2023 | 5,000 | 209,726 (0%) | 0% | 4.6 | 22,900 | Common Stock |
| CorMedix Inc | Joseph Todisco | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.30 per share. | 10 May 2023 | 37,443 | 204,726 (0%) | 0% | 5.3 | 198,448 | Common Stock |
| CorMedix Inc | Joseph Todisco | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2023 | 400,000 | 400,000 | - | - | Stock Option (Right to Buy Common Stock) | |
| CorMedix Inc | Joseph Todisco | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 3.82 per share. | 15 Nov 2022 | 20,000 | 242,169 (0%) | 0% | 3.8 | 76,400 | Common Stock |
| CorMedix Inc | Joseph Todisco | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 3.92 per share. | 24 Aug 2022 | 4,700 | 222,169 (0%) | 0% | 3.9 | 18,424 | Common Stock |
| CorMedix Inc | Joseph Todisco | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 3.38 per share. | 16 May 2022 | 10,000 | 217,469 (0%) | 0% | 3.4 | 33,800 | Common Stock |
| CorMedix Inc | Joseph Todisco | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 May 2022 | 500,000 | 500,000 | - | - | Stock Option (Right to Buy Common Stock) | |
| CorMedix Inc | Joseph Todisco | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 May 2022 | 207,469 | 207,469 (0%) | 0% | 0 | Common Stock | |
| Amneal Pharmaceuticals Inc... | Joseph Todisco | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 May 2022 | 4,442 | 328,756 (0%) | 0% | - | Class A Common Stock | |
| Amneal Pharmaceuticals Inc... | Joseph Todisco | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 May 2022 | 4,442 | 0 | - | - | Restricted Stock Units | |
| Amneal Pharmaceuticals Inc... | Joseph Todisco | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.40 per share. | 07 May 2022 | 1,562 | 327,194 (0%) | 0% | 3.4 | 5,311 | Class A Common Stock |
| Amneal Pharmaceuticals Inc... | Joseph Todisco | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 289,856 | 289,856 | - | - | Performance-Based Restricted Stock Units | |
| Amneal Pharmaceuticals Inc... | Joseph Todisco | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 144,928 | 144,928 | - | - | Restricted Stock Units | |
| Amneal Pharmaceuticals Inc... | Joseph Todisco | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2022 | 26,544 | 333,645 (0%) | 0% | - | Class A Common Stock | |
| Amneal Pharmaceuticals Inc... | Joseph Todisco | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2022 | 26,544 | 79,634 | - | - | Restricted Stock Units | |
| Amneal Pharmaceuticals Inc... | Joseph Todisco | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2022 | 11,111 | 11,111 | - | - | Restricted Stock Units | |
| Amneal Pharmaceuticals Inc... | Joseph Todisco | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2022 | 11,111 | 311,007 (0%) | 0% | - | Class A Common Stock | |
| Amneal Pharmaceuticals Inc... | Joseph Todisco | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.45 per share. | 01 Mar 2022 | 9,331 | 324,314 (0%) | 0% | 4.5 | 41,523 | Class A Common Stock |
| Amneal Pharmaceuticals Inc... | Joseph Todisco | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.45 per share. | 01 Mar 2022 | 3,906 | 307,101 (0%) | 0% | 4.5 | 17,382 | Class A Common Stock |
| Amneal Pharmaceuticals Inc... | Joseph Todisco | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2022 | 29,684 | 59,367 | - | - | Restricted Stock Units | |
| Amneal Pharmaceuticals Inc... | Joseph Todisco | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2022 | 29,684 | 311,003 (0%) | 0% | - | Class A Common Stock | |
| Amneal Pharmaceuticals Inc... | Joseph Todisco | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.59 per share. | 27 Feb 2022 | 11,107 | 299,896 (0%) | 0% | 4.6 | 50,981 | Class A Common Stock |
| Amneal Pharmaceuticals Inc... | Joseph Todisco | Executive Vice President | Sale of securities on an exchange or to another person at price $ 4.10 per share. | 02 Dec 2021 | 1,500 | 281,319 (0%) | 0% | 4.1 | 6,150 | Class A Common Stock |
| Amneal Pharmaceuticals Inc... | Joseph Todisco | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 May 2021 | 4,441 | 284,381 (0%) | 0% | - | Class A Common Stock | |
| Amneal Pharmaceuticals Inc... | Joseph Todisco | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 May 2021 | 4,441 | 4,442 | - | - | Restricted Stock Units | |
| Amneal Pharmaceuticals Inc... | Joseph Todisco | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.20 per share. | 07 May 2021 | 1,562 | 282,819 (0%) | 0% | 5.2 | 8,122 | Class A Common Stock |
| Amneal Pharmaceuticals Inc... | Joseph Todisco | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.75 per share. | 15 Mar 2021 | 36,330 | 316,270 (0%) | 0% | 2.8 | 99,908 | Class A Common Stock |
| Amneal Pharmaceuticals Inc... | Joseph Todisco | Executive Vice President | Sale of securities on an exchange or to another person at price $ 6.82 per share. | 15 Mar 2021 | 36,330 | 279,940 (0%) | 0% | 6.8 | 247,865 | Class A Common Stock |
| Amneal Pharmaceuticals Inc... | Joseph Todisco | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2021 | 36,330 | 36,331 | - | - | Stock Option (Right to Buy) | |
| Amneal Pharmaceuticals Inc... | Joseph Todisco | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 212,356 | 212,356 | - | - | Performance-Based Restricted Stock Units | |
| Amneal Pharmaceuticals Inc... | Joseph Todisco | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 106,178 | 106,178 | - | - | Restricted Stock Units | |
| Amneal Pharmaceuticals Inc... | Joseph Todisco | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2021 | 29,683 | 89,051 | - | - | Restricted Stock Units | |
| Amneal Pharmaceuticals Inc... | Joseph Todisco | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2021 | 29,683 | 283,707 (0%) | 0% | - | Class A Common Stock | |
| Amneal Pharmaceuticals Inc... | Joseph Todisco | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2021 | 11,111 | 283,846 (0%) | 0% | - | Class A Common Stock | |
| Amneal Pharmaceuticals Inc... | Joseph Todisco | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2021 | 11,111 | 22,222 | - | - | Restricted Stock Units | |
| Amneal Pharmaceuticals Inc... | Joseph Todisco | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.39 per share. | 27 Feb 2021 | 10,972 | 272,735 (0%) | 0% | 5.4 | 59,139 | Class A Common Stock |
| Amneal Pharmaceuticals Inc... | Joseph Todisco | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.18 per share. | 27 Feb 2021 | 3,906 | 279,940 (0%) | 0% | 5.2 | 20,233 | Class A Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges